# EDGAR Filing Document

**Accession Number:** 0001157075
**File Stem:** 0000000000-25-010346
**Filing Date:** 2025-9
**Character Count:** 2455
**Document Hash:** a570da064604923376ec8fcc31da86a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010346.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0000000000-25-010346

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250923

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PharmaCyte Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001157075
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 621772151
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290311

**BUSINESS ADDRESS:**
- **STREET 1:** 3960 HOWARD HUGHES PARKWAY
- **STREET 2:** SUITE 500
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89169
- **BUSINESS PHONE:** (917) 595.2850

**MAIL ADDRESS:**
- **STREET 1:** 3960 HOWARD HUGHES PARKWAY
- **STREET 2:** SUITE 500
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89169

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUVILEX, INC.
- **DATE OF NAME CHANGE:** 20090324

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EFOODSAFETY COM INC
- **DATE OF NAME CHANGE:** 20010808
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001683168-25-007041

## Text-Extract

```

                                                           September 23, 2025

Carlos Trujillo
Chief Financial Officer
PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV 89169

        Re: PharmaCyte Biotech, Inc.
            Registration Statement on Form S-3
            Filed September 17, 2025
            File No. 333-290311
Dear Carlos Trujillo:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jimmy McNamara at 202-551-7349 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Kenneth Koch

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._